Cargando…

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks

Counterfeit drugs are inherently dangerous and a growing problem; counterfeiters are becoming increasingly sophisticated. Growth of the counterfeit medication market is attributable in part to phosphodiesterase type 5 inhibitor (PDE5i) medications for erectile dysfunction (ED). Millions of counterfe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jackson, G, Arver, S, Banks, I, Stecher, V J
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2010
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069491/ https://www.ncbi.nlm.nih.gov/pubmed/20088883 http://dx.doi.org/10.1111/j.1742-1241.2009.02328.x

Ejemplares similares

Counterfeit filtering facepiece respirators are posing an additional risk to health care workers during COVID-19 pandemic
por: Ippolito, Mariachiara, et al.
Publicado: (2020)

Comparative dissolution study on counterfeit medicines of PDE-5 inhibitors
por: Deconinck, E., et al.
Publicado: (2014)

COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020)

Counterfeits
Publicado: (1876)

Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis
por: Stridh, Alexander, et al.
Publicado: (2020)

AB030. Evolution of phosphodiesterase type 5 inhibitors
por: Moon, Du Geon
Publicado: (2016)

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy
por: Buckley, Mitchell S, et al.
Publicado: (2010)

Counterfeit Drugs
Publicado: (1927)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
por: Gheorghiu, Oana Ramona Cătălina, et al.
Publicado: (2023)

Phosphodiesterase type 5 inhibitors: Irrational use in Saudi Arabia
por: Alshahrani, Saad, et al.
Publicado: (2016)

Phosphodiesterase Type 5 Inhibitors and sudden sensorineural hearing loss
por: Barreto, Monique Antunes de Souza Chelminski, et al.
Publicado: (2015)

Safety and Quality Issues of Counterfeit Lithium-Ion Cells
por: Joshi, Tapesh, et al.
Publicado: (2023)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder
por: Balog, Brian M., et al.
Publicado: (2019)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
por: Corinaldesi, C., et al.
Publicado: (2015)

Revisiting the halogen bonding between phosphodiesterase type 5 and its inhibitors
por: Jedwabny, Wiktoria, et al.
Publicado: (2019)

Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?
por: Mondaini, Nicola
Publicado: (2020)

Lumbago and Its Counterfeits
Publicado: (1902)

Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies
por: Han, Xinming, et al.
Publicado: (2018)

Let’s rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy
por: Kim, Su Jin, et al.
Publicado: (2016)

The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue
por: Zucchi, A., et al.
Publicado: (2019)

Phosphodiesterase-5 inhibitors for colon cancer chemoprevention
por: Islam, Bianca N., et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
por: Hutchings, David Charles, et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs
por: Abassi, Zaid, et al.
Publicado: (2015)

Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis
por: Feng, Shijian, et al.
Publicado: (2018)

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews
por: Pyrgidis, Nikolaos, et al.
Publicado: (2021)

Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review
por: Barroso, Francisco, et al.
Publicado: (2021)

Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
por: Newby, Danielle
Publicado: (2022)

Chronic Rheumatism and Its Counterfeits
por: Fothergill, J. Milner
Publicado: (1870)

Nerve Counterfeits of Uterine Disease
por: Ingraham, Henry D.
Publicado: (1892)

Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma
por: Loeb, Stacy, et al.
Publicado: (2017)

The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History
por: Elhwuegi, AS
Publicado: (2016)

Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate
por: Zhang, Wenhao, et al.
Publicado: (2015)

Phosphodiesterase type 5 and cancers: progress and challenges
por: Barone, Ines, et al.
Publicado: (2017)

Usage and perceptions of phosphodiesterase type 5 inhibitors among the male partners of infertile couples
por: Song, Seung-Hun, et al.
Publicado: (2016)

Phosphodiesterase type 5 inhibitors usage and prostate cancer: a match-paired analysis
por: Machen, G. Luke, et al.
Publicado: (2017)

Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review
por: da Cruz, Natasha Ferreira Santos, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qq0r35562fimaqrk9vau3jgj4l